Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Net Income (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Net Income for 6 consecutive years, with -$5.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 106.42% to -$5.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$17.1 million, a 35.64% decrease, with the full-year FY2024 number at -$11.1 million, up 18.27% from a year prior.
  • Net Income was -$5.4 million for Q3 2025 at Vivos Therapeutics, down from -$5.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $17.9 million in Q4 2022 to a low of -$7.4 million in Q4 2021.
  • A 5-year average of -$3.1 million and a median of -$4.0 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 197.29% in 2021, then soared 340.91% in 2022.
  • Vivos Therapeutics' Net Income stood at -$7.4 million in 2021, then skyrocketed by 340.91% to $17.9 million in 2022, then plummeted by 124.09% to -$4.3 million in 2023, then surged by 34.29% to -$2.8 million in 2024, then plummeted by 91.02% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Income are -$5.4 million (Q3 2025), -$5.0 million (Q2 2025), and -$3.9 million (Q1 2025).